Evidence map›Paper›PMID 34191659›Full record

ArticleScience progress

Disparity between scientific accomplishment and biotechnology availability in Brazil.

Lucia Maria Almeida Braz, Roozbeh Tahmasebi, Antonio Charlys da Costa, Steven S Witkin

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lucia Maria Almeida BrazInstituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.ORCID 0000-0002-6493-465X
Roozbeh TahmasebiInstituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.ORCID 0000-0001-9631-5530
Antonio Charlys da CostaInstituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.
Steven S WitkinInstituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite being among the world's leaders in scientific output, Brazil ranks 66th among countries in the production of reagents and supplies needed for state-of-the-art scientific analyses. The production of needed reagents and equipment for experimental analyses and patient diagnostics is sorely lacking within Brazil and explicit in this pandemic period caused by SARS-CoV-2. A significant fraction of resources from Brazilian funding agencies is now being transferred to companies in other countries for the purchase of essential scientific-related products. Is this sustainable? Therefore it is necessary to draw the attention of all the world and Brazilian society about this situation.

Indexed as

SARS-CoV-2Biomedical TechnologyBiotechnologyBrazilCOVID-19HumansResearchBrazilian biotechnologyBrazilian entrepreneursBrazilian scientistsfor-profit industriesNeglected technological investmentstart-up companies

Identifiers

PMID34191659
PMCPMC10454951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.